LIFEPAK 1000 DEFIBRILLATOR, LIFEPAK 20 DEFIBRILLATOR/ MONITOR, LIFEPAK 20E DEFIBRILLATOR/ MONITOR, LIFEPAK 15 MONITOR/DE
Physio-Control, Inc. · Decision date Jul 2, 2018
What did the FDA approve?
FDA approved a PMA supplement from Physio-Control, Inc. covering the LIFEPAK 1000 defibrillator, the LIFEPAK 1000 lithium-ion rechargeable battery, refurbished LIFEPAK 20 defibrillator/monitors, the LIFEPAK 20e defibrillator/monitor, the LIFEPAK 15 monitor/defibrillator, and the LIFEPAK lithium-ion rechargeable battery for use with the LIFEPAK 15. The decision date is July 2, 2018, and the product code is MKJ under the cardiovascular specialty.
The statement lists AED-mode indications. The LIFEPAK 1000 is for patients in cardiopulmonary arrest who are unresponsive, not breathing normally, and showing no signs of circulation; it may be used on adults and children 8 years or older or over 25 kg, and on younger or lighter children with Infant/Child Reduced Energy Defibrillation Electrodes. The LIFEPAK 20, 20e, and 15 AED modes are for unconscious, pulseless patients not breathing normally, and are not intended for pediatric patients under 8 years old. The statement does not describe the specific change covered by the supplement.
FDA approval order statement
Approval for the LIFEPAK 1000 Defibrillator, LIFEPAK 1000 Defibrillator Lithium-ion Rechargeable Battery, LIFEPAK 20 Defibrillator/ Monitor (Refurbished), LIFEPAK 20e Defibrillator/ Monitor, LIFEPAK 15 Monitor/Defibrillator, and LIFEPAK Lithium-ion Rechargeable Battery (for use with the LIFEPAK 15 Monitor/Defibrillator) These devices are indicated for use as follows:LIFEPAK 1000 DefibrillatorThe defibrillator is to be used in AED mode only on patients who are in cardiopulmonary arrest. The patient must be unresponsive, not breathing normally, and showing no signs of circulation. The defibrillator may be used with standard defibrillation pads only on adults and children who are 8 years old or more or who weigh more than 25 kg (55 lbs). The defibrillator may be used on children who are less than 8 years old or weigh less than 25 kg (55 lbs) with Infant/Child Reduced Energy Defibrillation Electrodes.LIFEPAK 20/20e Defibrillator/Monitors The AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing normally before using the defibrillator to analyze the patients ECG rhythm. In AED mode, the LIFEPAK 20 and LIFEPAK 20e defibrillator/monitor is not intended for use on pediatric patients less than 8 years old. LIFEPAK 15 Defibrillator/Monitors AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing normally before using the defibrillator to analyze the patients ECG rhythm. In AED mode, the LIFEPAK 15 monitor/defibrillator is not intended for use on pediatric patients less than 8 years old.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 2, 2018
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160026
- Regulatory pathway
- Premarket approval application
- Applicant
- Physio-Control, Inc.
- Product code
- MKJ
- Decision code
- APPR
- Decision date
- Jul 2, 2018
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated external defibrillators (non-wearable).
- Applicant
- Physio-Control, Inc.
- Product code
- MKJ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160026 received
Application receipt date recorded by FDA.
P160026 · FDA decision
APPR
P160026/S069 · Related supplement
LIFEPAK 35 monitor/defibrillator
P160026/S073 · Related supplement
LIFEPAK 15 monitor/defibrillator
P160026/S074 · Related supplement
LIFEPAK 1000 DEFIBRILLATOR, LIFEPAK 20 DEFIBRILLATOR/ MONITOR, LIFEPAK 20E DEFIBRILLATOR/ MONITOR, LIFEPAK 15 MONITOR/DE
P160026/S076 · Related supplement
LIFEPAK 35 monitor/defibrillator
Timeline entries are records held by MedtechLedger for P160026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIFEPAK 35 monitor/defibrillatorP160026/S069 | Physio-Control, Inc. | PMA supplement | Sep 2, 2026 | FDA |
LIFEPAK 15 monitor/defibrillatorP160026/S073 | Physio-Control, Inc. | PMA supplement | Sep 10, 2026 | FDA |
| Physio-Control, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
LIFEPAK 35 monitor/defibrillatorP160026/S076 | Physio-Control, Inc. | PMA supplement | Oct 29, 2026 | FDA |
Explore the linked device profile
Other records with product code MKJ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AED 3 Defibrillator with Uni-PadzP160015/S029 | ZOLL MEDICAL CORPORATION | PMA supplement | Oct 16, 2026 | FDA |
ZOLL R Series Monitor/DefibrillatorP160022/S056 | ZOLL MEDICAL CORPORATION | PMA supplement | Oct 16, 2026 | FDA |
| ZOLL MEDICAL CORPORATION | PMA supplement | Oct 2, 2026 | FDA | |
| ZOLL MEDICAL CORPORATION | PMA approval | Dec 27, 2017 | FDA | |
| ZOLL MEDICAL CORPORATION | PMA approval | May 26, 2017 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Physio-Control, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 11811 Willows Rd. NE, Redmond, WA, 98052
Sources and methodology
- Original FDA record: P160026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




